13F Holdings
中文EN

MREO Mereo BioPharma Group plc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1719714 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY35.2%
TTM EPS YoY40.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-76.6%
ROA-64.8%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets19.8%
Debt / equity0.00x
Current ratio5.22x
Interest coverage-440.64x

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-11.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31 · USDFY20242024-12-31 · USDFY20232023-12-31 · USDFY20222022-12-31 · GBPFY20212021-12-31 · GBP
Income statement
Revenue$500,000$0$10.00M$0USD36.46M
Cost of revenue———-936,00017.91M
Gross profit————18.56M
R&D expense$17.77M$20.93M$17.42M24.96M23.56M
SG&A expense$23.01M$26.43M$18.42M$26.11MUSD—
Operating income-$40.11M-$47.36M-$28.42M-43.57M-20.94M
Interest expense$255,000$1.37M$2.88M3.36M4.02M
Pretax income-$41.88M-$43.25M-$30.00M-36.09M14.24M
Income tax$0$0-$532,000-1.90M1.52M
Net income-$41.88M-$43.25M-$29.47M-34.20M12.72M
EBITDA-$39.95M-$47.22M-$28.25M-42.84M-20.29M
EPS (basic)-0.05-0.06-0.04-0.060.02
EPS (diluted)-0.05-0.06-0.04-0.06-0.05
Weighted avg. shares (diluted)797.12M739.62M659.45M603.20M555.28M
Balance sheet
Cash & equivalents$40.99M$69.80M$57.42M56.33M94.30M
Receivables———762,000—
Current assets$45.02M$74.76M$63.76M62.13M99.32M
PP&E, net$137,000$257,000$405,0001.83M2.53M
Intangibles$516,000$643,000$1.09M24.12M24.56M
Total assets$45.92M$76.39M$66.50M88.08M126.42M
Current liabilities$4.30M$13.85M$9.49M24.68M12.54M
Short-term debt———11.09M0
Long-term debt———014.38M
Total debt———11.09M14.38M
Total liabilities$5.00M$15.42M$15.96M26.21M38.41M
Shareholders' equity$40.92M$60.97M$50.54M$51.40MUSD$92.20MUSD
Net debt———-45.25M-79.91M
Cash flow statement
Operating cash flow-$30.97M-$32.83M-$21.13M-38.82M-5.24M
Capital expenditure$20,000$0$010,000535,000
Free cash flow-$30.99M-$32.83M-$21.13M-38.83M-5.77M
Investing cash flow-$20,000-$699,000-$419,0001.50M-421,000
Financing cash flow$327,000$46.15M$7.97M-784,00077.65M
Depreciation & amortization$157,000$143,000$171,000727,000642,000
Stock-based compensation$7.60M$7.39M$4.92M3.86M3.30M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.